Semaglutide is a medication used to manage weight and blood sugar, and it is not currently on the Medication Deferral List maintained by major blood and plasma donation organizations like the American Red Cross or CSL Plasma
Ozempic is paving the way for other GLP-1 drugs to treat conditions beyond kidney disease The FLOW trial results, along with the recent announcement that Wegovy is approved to reduce cardiovascular risk in people with obesity, are the latest indications that these drugs have benefits for conditions beyond their original intended treatment of type 2 diabetes
The study, conducted by researchers in the US and Brazil, focused on the use of Ozempic in treating metabolic dysfunction-associated steatotic liver disease, or MASLD: the most common cause of chronic liver disease and of liver-related deaths
[6] Although not FDA-approved for the treatment of individuals with PCOS, Ozempic has demonstrated promising results in treating insulin resistance in these individuals
Physical activity and sedentary behavior in people with bipolar disorder: A systematic review and meta-analysis
Slower escalation options Some providers extend the escalation timeline, keeping patients at each dose level for 6 to 8 weeks instead of 4
